{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:06:33Z","timestamp":1788926793783,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03347-x","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:03:39Z","timestamp":1784714619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design and evaluation of an EpCAM-specific peptide\u2013diphtheria toxin fusion (DT-SNFYMPL) for targeted epithelial cancer treatment"],"prefix":"10.1007","volume":"43","author":[{"given":"Sara","family":"Rafia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Tabanmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Habibi-Anbouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohre","family":"Eftekhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Erfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5832-1822","authenticated-orcid":false,"given":"Fatemeh","family":"Kazemi-Lomedasht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"3347_CR1","doi-asserted-by":"publisher","unstructured":"Schnell U, Cirulli V, Giepmans BN. EpCAM: structure and function in health and disease. Biochim Biophys Acta . 2013;1828(8):1989\u20132001. https:\/\/doi.org\/10.1016\/j.bbamem.2013.04.018","DOI":"10.1016\/j.bbamem.2013.04.018"},{"issue":"6","key":"3347_CR2","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/S0002-9440(10)63570-5","volume":"163","author":"MJ Winter","year":"2003","unstructured":"Winter MJ, et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163(6):2139\u201348.","journal-title":"Am J Pathol"},{"issue":"1","key":"3347_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"PT Went","year":"2004","unstructured":"Went PT, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122\u20138.","journal-title":"Hum Pathol"},{"issue":"1","key":"3347_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1040-8428(01)00131-7","volume":"40","author":"LS Schwartzberg","year":"2001","unstructured":"Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol\/Hematol. 2001;40(1):17\u201324.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"6","key":"3347_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","volume":"36","author":"D Seimetz","year":"2010","unstructured":"Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM\u00d7 anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36(6):458\u201367.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3347_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00003072-200001000-00013","volume":"25","author":"MR Straka","year":"2000","unstructured":"Straka MR, Joyce JM, Myers DT. Tc-99m nofetumomab merpentan complements an equivocal bone scan for detecting skeletal metastatic disease from lung cancer. Clin Nucl Med. 2000;25(1):54.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"3347_CR7","first-page":"650","volume":"63","author":"A Coulson","year":"2015","unstructured":"Coulson A, Levy A, Gossell-Williams M. Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J. 2015;63(6):650.","journal-title":"West Indian Med J"},{"issue":"1","key":"3347_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/14756366.2020.1758690","volume":"35","author":"E Karami","year":"2020","unstructured":"Karami E, et al. A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis. J Enzyme Inhib Med Chem. 2020;35(1):1233\u20139.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"2","key":"3347_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.canlet.2003.08.011","volume":"202","author":"T Oyama","year":"2003","unstructured":"Oyama T, et al. Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett. 2003;202(2):219\u201330.","journal-title":"Cancer Lett"},{"issue":"5","key":"3347_CR10","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1021\/acs.molpharmaceut.9b00185","volume":"16","author":"X Ma","year":"2019","unstructured":"Ma X, et al. Identification of tumor specific peptide as EpCAM ligand and its potential diagnostic and therapeutic clinical application. Mol Pharm. 2019;16(5):2199\u2013213.","journal-title":"Mol Pharm"},{"issue":"1","key":"3347_CR11","first-page":"27","volume":"25","author":"M Hosseininejad-Chafi","year":"2022","unstructured":"Hosseininejad-Chafi M, et al. In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin. Iran J Basic Med Sci. 2022;25(1):27.","journal-title":"Iran J Basic Med Sci"},{"issue":"4","key":"3347_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12033-022-00565-2","volume":"65","author":"R Roshan","year":"2023","unstructured":"Roshan R, et al. A novel immunotoxin targeting epithelial cell adhesion molecule using single domain antibody fused to diphtheria toxin. Mol Biotechnol. 2023;65(4):637\u201344.","journal-title":"Mol Biotechnol"},{"issue":"2","key":"3347_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/08923973.2021.1888114","volume":"43","author":"S Naderi","year":"2021","unstructured":"Naderi S, et al. Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin. Immunopharmacol Immunotoxicol. 2021;43(2):230\u20138.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"3347_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/mab.2020.0043","volume":"40","author":"A Mousavi","year":"2021","unstructured":"Mousavi A, et al. In Vivo tumor therapy with novel immunotoxin containing programmed cell death protein-1 and diphtheria toxin. Monoclon Antibodies Immunodiagnosis Immunotherapy. 2021;40(3):113\u20137.","journal-title":"Monoclon Antibodies Immunodiagnosis Immunotherapy"},{"issue":"3","key":"3347_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/toxins3030294","volume":"3","author":"JR Murphy","year":"2011","unstructured":"Murphy JR. Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxins. 2011;3(3):294\u2013308.","journal-title":"Toxins"},{"issue":"3","key":"3347_CR16","doi-asserted-by":"publisher","first-page":"p100014","DOI":"10.1016\/j.crmeth.2021.100014","volume":"1","author":"W Zheng","year":"2021","unstructured":"Zheng W, et al. Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations. Cell Rep methods. 2021;1(3):p100014.","journal-title":"Cell Rep methods"},{"issue":"W1","key":"3347_CR17","doi-asserted-by":"publisher","first-page":"W291","DOI":"10.1093\/nar\/gkx366","volume":"45","author":"C Zhang","year":"2017","unstructured":"Zhang C, Freddolino PL, Zhang Y. COFACTOR: improved protein function prediction by combining structure, sequence and protein\u2013protein interaction information. Nucleic Acids Res. 2017;45(W1):W291\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"3347_CR18","doi-asserted-by":"publisher","first-page":"W174","DOI":"10.1093\/nar\/gkv342","volume":"43","author":"J Yang","year":"2015","unstructured":"Yang J, Zhang Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 2015;43(W1):W174\u201381.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3347_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/15569543.2016.1244552","volume":"36","author":"M Bagheri","year":"2017","unstructured":"Bagheri M, et al. Development of a recombinant camelid specific diabody against the heminecrolysin fraction of Hemiscorpius lepturus scorpion. Toxin Reviews. 2017;36(1):7\u201311.","journal-title":"Toxin Reviews"},{"key":"3347_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.molimm.2020.10.021","volume":"129","author":"R Roshan","year":"2021","unstructured":"Roshan R, et al. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy. Mol Immunol. 2021;129:70\u20137.","journal-title":"Mol Immunol"},{"issue":"1","key":"3347_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/1547691X.2018.1526234","volume":"16","author":"M Ahadi","year":"2019","unstructured":"Ahadi M, et al. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor. J Immunotoxicol. 2019;16(1):34\u201342.","journal-title":"J Immunotoxicol"},{"key":"3347_CR22","doi-asserted-by":"crossref","unstructured":"Karami E, et al. Effective blocking of neuropilin-1activity using oligoclonal nanobodies targeting different epitopes. Prep Biochem Biotechnol. 2022:1\u20139.","DOI":"10.1080\/10826068.2022.2111583"},{"issue":"5","key":"3347_CR23","doi-asserted-by":"publisher","first-page":"pe1007105","DOI":"10.1371\/journal.ppat.1007105","volume":"14","author":"J Wang","year":"2018","unstructured":"Wang J, et al. Caspase-11-dependent pyroptosis of lung epithelial cells protects from melioidosis while caspase-1 mediates macrophage pyroptosis and production of IL-18. PLoS Pathog. 2018;14(5):pe1007105.","journal-title":"PLoS Pathog"},{"issue":"5","key":"3347_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/08923973.2018.1505907","volume":"40","author":"R Baharlou","year":"2018","unstructured":"Baharlou R, et al. An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization. Immunopharmacol Immunotoxicol. 2018;40(5):368\u201374.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"3347_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/dta.2693","volume":"12","author":"A Sadeghi","year":"2020","unstructured":"Sadeghi A, et al. Development of a mono-specific anti\u2010VEGF bivalent nanobody with extended plasma half\u2010life for treatment of pathologic neovascularization. Drug Test Anal. 2020;12(1):92\u2013100.","journal-title":"Drug Test Anal"},{"key":"3347_CR26","doi-asserted-by":"crossref","unstructured":"Albert F, et al. Intravesical therapy with the trifunctional anti-EpCAM\/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk NMIBC (CATUNIBLA phase I trial). American Society of Clinical Oncology; 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.e16555"},{"issue":"10","key":"3347_CR27","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/s44321-024-00116-z","volume":"16","author":"SK Gill","year":"2024","unstructured":"Gill SK, et al. An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies. EMBO Mol Med. 2024;16(10):2638.","journal-title":"EMBO Mol Med"},{"key":"3347_CR28","doi-asserted-by":"publisher","first-page":"105673","DOI":"10.1016\/j.jddst.2024.105673","volume":"96","author":"D Zhukova","year":"2024","unstructured":"Zhukova D, et al. Nontoxic diphtheria toxin derivates CRM197 and B-fragment can serve as the means for targeted curcumin delivery into sensitive cancer cells. J Drug Deliv Sci Technol. 2024;96:105673.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3347_CR29","doi-asserted-by":"publisher","unstructured":"Tian S et al. Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms. Cell Rep. 2022;38(10): 110476 https:\/\/doi.org\/10.1016\/j.celrep.2022.110476","DOI":"10.1016\/j.celrep.2022.110476"},{"issue":"1","key":"3347_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12951-023-02223-4","volume":"21","author":"X Yu","year":"2023","unstructured":"Yu X, et al. Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies. J Nanobiotechnol. 2023;21(1):454.","journal-title":"J Nanobiotechnol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03347-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:21:37Z","timestamp":1788924097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03347-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3347"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03347-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures conducted in this study were approved by the Ethical Committee of the Islamic Azad University, North Tehran Branch (IR.IAU.TNB.REC.1404.030), in accordance with the institutional guidelines and national regulations for the ethical conduct of research involving live vertebrates.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"229"}}